0000882095 false 0000882095 2020-01-27 2020-01-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 28, 2020

  

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction
of incorporation) 		0-19731
(Commission File No.)

94-3047598
(IRS Employer

Identification No.)

 

333 LAKESIDE DRIVE, FOSTER CITY, California

(Address of principal executive offices)

 

94404

(Zip Code)

 

(650) 574-3000

(Registrant’s telephone number, including area code)

  

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

(d)       Appointment of a Director.

 

At a meeting held on January 28, 2020, the Board of Directors (the Board) of Gilead Sciences, Inc. (the Company) elected Dr. Sandra J. Horning to serve on the Board, effective immediately. Dr. Horning was also appointed as a member of the Nominating and Corporate Governance Committee and the Scientific Committee of the Board. There is no arrangement or understanding between Dr. Horning and any other persons pursuant to which Dr. Horning was selected as a director, and there are no related party transactions involving Dr. Horning that are reportable under Item 404(a) of Regulation S-K.

 

Dr. Horning will participate in the Company’s standard non-employee director compensation programs. Pursuant to these arrangements, for the remainder of the 2019-2020 director compensation period, Dr. Horning will receive:

 

(1) A pro-rated equity grant, consisting of options to purchase 3,837 shares of the Company’s common stock and restricted stock units covering an additional 632 shares of the Company’s common stock. These grants will be made under the Company’s 2004 Equity Incentive Plan (as amended and restated, the Plan).

 

(2) A pro-rated cash retainer in the amount of $48,836.

 

A description of the Plan and compensation practices for non-employee directors can be found in our Definitive Proxy Statement filed with the Securities and Exchange Commission (SEC) on March 25, 2019 in connection with the Company’s 2019 Annual Meeting of Stockholders. The Plan is attached as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on May 12, 2017.

 

A copy of the Company’s press release announcing Dr. Horning’s election to the Board is attached as Exhibit 99.1 to this report.

 

(c)        Appointment of Principal Accounting Officer.

 

On January 29, 2020, the Company designated Diane E. Wilfong, Senior Vice President, Corporate Controller and Chief Accounting Officer, as the principal accounting officer for purposes of the Company’s filings with the SEC, effective immediately. Ms. Wilfong, age 58, joined the Company in February 2016 as Vice President, Controller and Chief Accounting Officer. Prior to joining the Company, Ms. Wilfong was Vice President, Controller and Principal Accounting Officer at Computer Sciences Corporation (now known as DXC Technology) from November 2014 to February 2016. Ms. Wilfong also served in similar roles at Caesars Entertainment Corporation and Eastman Kodak Company. Ms. Wilfong is a certified public accountant (inactive) and began her career with PricewaterhouseCoopers. Ms. Wilfong received a B.S. in Business Administration from the University of North Carolina at Chapel Hill.

 

There is no arrangement or understanding between Ms. Wilfong and any other persons pursuant to which Ms. Wilfong was selected as an officer, and there are no related party transactions involving Ms. Wilfong that are reportable under Item 404(a) of Regulation S-K. Ms. Wilfong does not have a family relationship with any director, executive officer or person nominated or chosen by the Company to become a director or executive officer of the Company. Ms. Wilfong has not entered into any material plan, contract, arrangement or amendment in connection with her designation as principal accounting officer.

 

Item 9.01 Financial Statements and Exhibits

 

(d)       Exhibits

 

The following exhibit 99.1 is furnished pursuant to this Item 9.01.

 

Exhibit

Number

  Description
99.1   Press Release by Gilead Sciences, Inc. dated January 30, 2020.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GILEAD SCIENCES, INC.
  (Registrant)
   
   
  /s/ Brett A. Pletcher
  Brett A. Pletcher
 

EVP, Corporate Affairs, General Counsel

and Corporate Secretary

 

Date:     January 31, 2020

 

 

Exhibit 99.1

 

 

  CONTACTS: Douglas Maffei, Investors
  (650) 522-2739
   
 

Amy Flood, Media

(650) 522-5643

 

For Immediate Release

  

SANDRA HORNING, MD, JOINS GILEAD SCIENCES’ BOARD OF DIRECTORS

 

Foster City, Calif., January 30, 2020 – Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Sandra Horning, MD, has been appointed to the company’s Board of Directors.

 

Dr. Horning retired in 2019 as Chief Medical Officer and Global Head of Product Development for Roche, after a 10-year career at Roche and Genentech during which she helped bring 15 new medicines to patients in disease areas including cancer, multiple sclerosis, influenza and blindness. Prior to her career at Roche, Dr. Horning spent 25 years as a practicing oncologist, investigator and tenured professor at Stanford University School of Medicine. From 2015 to 2018, Dr. Horning served on the Foundation Medicine Board of Directors and she currently serves as an advisor to EQRx.

 

“We are very pleased to welcome Sandra Horning to our Board of Directors,” said Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences. “Sandra has significant industry expertise and vast experience in drug development across multiple therapeutic areas. In addition, she brings the perspective of a leading physician who has spent more than two decades caring for patients with cancer. Sandra’s presence on our Board will be a tremendous asset as we enter the next chapter for Gilead with the goal of rapidly advancing new, transformative medicines.”

 

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

 

# # #

 

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

  

Gilead Sciences, Inc.  333 Lakeside Drive  Foster City, CA 94404 USA www.gilead.com
phone 650 574 3000 facsimile 650 578 9264